Bohm, M., Kemp, E. orcid.org/0000-0002-0313-8916, Metze, D. et al. (4 more authors) (2021) Alemtuzumab-induced halo nevus-like hypopigmentation – New insights into secondary skin autoimmunity in response to an immune cell-depleting antibody. Journal of the European Academy of Dermatology and Venereology, 35 (1). e28-e30. ISSN 0926-9959
Abstract
We describe a 33‐year‐old male patient who developed hypopigmentation around his melanocytic nevi with disappearance of the nevi in August 2018. In June 2016 he had been diagnosed with highly active RRMS and treated with alemtuzumab in September 2016 for the first time. In September 2017 another cycle of alemtuzumab was administered. The patient’s family history for vitiligo was unremarkable and he had no autoimmune thyroid disease.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2020 European Academy of Dermatology and Venereology. This is an author-produced version of a paper subsequently published in Journal of the European Academy of Dermatology and Venereology. Uploaded in accordance with the publisher's self-archiving policy. |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Sheffield Teaching Hospitals |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 22 Jun 2020 10:50 |
Last Modified: | 04 Nov 2021 16:14 |
Status: | Published |
Publisher: | Wiley |
Refereed: | Yes |
Identification Number: | 10.1111/jdv.16781 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:161994 |